The U.S. Food and Drug Administration (FDA) recently granted expedited approval of an innovative antiviral for treating non-hospitalized adult and adolescent patients who are at high risk of progression to severe COVID-19.
On January 21, 2022, the FDA issued a supplemental new drug application (sNDA) for Veklury® (remdesivir). This nucleotide analog has been the antiviral standard of care for treating patients hospitalized with COVID-19.
Read More
